The IPO Outlook For The Week: One Lonely Biotech

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud.

Aridis Pharmaceuticals, Inc. (ARDS) will issue 2 million shares between $13 and $15 Tuesday on the Nasdaq. Based in California, the biotech firm develops therapies for antibiotic-resistant infections, including hospital-acquired infections and cystic fibrosis. Aridis has completed Phase 2 trials for one candidate, is conducting Phase 2 studies on two others and has three more in preclinical stages.

Related Links:

5 Reasons Why 2018 Could Be Good For IPO ETFs

3 Tech IPOs We Want In 2018